Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.65 |
| ▸ | FOLH1 | Q04609 | 6/20 | 0.62 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.62 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.62 |
| ▸ | GNPAT | O15228 | 1/20 | 0.57 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.51 |
| ▸ | GART | P22102 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14167625 | 1.00 | NOD1 (0.65) | NOD1FOLH1RIMKLANAALAD2GNPAT | |
| SCHEMBL19049826 | 1.00 | NOD1 (0.65) | NOD1FOLH1RIMKLANAALAD2GNPAT | |
| SCHEMBL29518246 | 1.00 | NOD1 (0.65) | NOD1FOLH1RIMKLANAALAD2GNPAT | |
| SCHEMBL19049828 | 1.00 | NOD1 (0.65) | NOD1FOLH1RIMKLANAALAD2GNPAT | |
| SCHEMBL4407799 | 1.00 | NOD1 (0.65) | NOD1FOLH1RIMKLANAALAD2GNPAT | |
| SCHEMBL19034801 | 1.00 | NOD1 (0.65) | NOD1FOLH1RIMKLANAALAD2GNPAT | |
| SCHEMBL13753507 | 1.00 | NOD1 (0.65) | NOD1FOLH1RIMKLANAALAD2GNPAT | |
| SCHEMBL19049830 | 0.98 | NOD1 (0.68) | NOD1FOLH1RIMKLANAALAD2GNPAT | |
| SCHEMBL14167660 | 0.98 | NOD1 (0.68) | NOD1FOLH1RIMKLANAALAD2GNPAT | |
| SCHEMBL19049823 | 0.98 | NOD1 (0.68) | NOD1FOLH1RIMKLANAALAD2GNPAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000770-A1 | LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USES THEREOF | BEIJING QL BIOPHARMACEUTICAL CO LTD (CN) | 2026-01-01 | — | — | US | disclosed |
| US-20250276068-A1 | PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USES THEREOF | BEIJING QL BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-09-04 | — | — | US | disclosed |
| US-12383623-B2 | Liquid pharmaceutical compositions of polypeptide conjugates and methods of uses thereof | BEIJING QL BIOPHARMACEUTICAL CO., LTD. (CN) | 2025-08-12 | — | — | US | disclosed |
| US-20240181016-A1 | POLYPEPTIDE CONJUGATES AND METHODS OF USES | BEIJING QL BIOPHARMACEUTICAL CO., LTD. (CN) | 2024-06-06 | — | — | US | disclosed |
| US-20240173416-A1 | PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USES THEREOF | BEIJING QL BIOPHARMACEUTICAL CO., LTD. (CN) | 2024-05-30 | — | — | US | disclosed |
| US-20230310616-A1 | LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USES THEREOF | BEIJING QL BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-10-05 | — | — | US | disclosed |
| US-11529394-B2 | Polypeptide conjugates and methods of uses | BEIJING QL BIOPHARMACEUTICAL CO., LTD. (CN) | 2022-12-20 | — | — | US | disclosed |
| US-11510990-B2 | Conjugates of fusion proteins of GLP-1 and FGF21 | BEIJING QL BIOPHARMACEUTICAL CO., LTD. (CN) | 2022-11-29 | — | — | US | disclosed |
| US-11453711-B2 | Fusion proteins of GLP-1 and GDF15 and conjugates thereof | BEIJING QL BIOPHARMACEUTICAL CO., LTD. (CN) | 2022-09-27 | — | — | US | disclosed |
| US-20220133856-A1 | POLYPEPTIDE CONJUGATES AND METHODS OF USES | BEIJING QL BIOPHARMACEUTICAL CO., LTD. (CN) | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11529394-B2 | Polypeptide conjugates and methods of uses | GLP1R, GIPR, IAPP | NOD1 1241/4885FOLH1 64/4885RIMKLA 2555/4885 |
| US-12383623-B2 | Liquid pharmaceutical compositions of polypeptide conjugates and methods of uses thereof | GLP1R, GIPR, IAPP | NOD1 621/4885FOLH1 108/4885RIMKLA 2455/4885 |
| US-20240181016-A1 | POLYPEPTIDE CONJUGATES AND METHODS OF USES | GLP1R, GIPR, IAPP | NOD1 1241/4885FOLH1 64/4885RIMKLA 2555/4885 |
| US-11453711-B2 | Fusion proteins of GLP-1 and GDF15 and conjugates thereof | GLP1R, IAPP, GIPR | NOD1 462/4885FOLH1 229/4885RIMKLA 2589/4885 |
| US-20230310616-A1 | LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USES THEREOF | GLP1R, GIPR, IAPP | NOD1 621/4885FOLH1 108/4885RIMKLA 2455/4885 |
| US-20250276068-A1 | PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USES THEREOF | GLP1R, GIPR, IAPP | NOD1 830/4885FOLH1 74/4885RIMKLA 2601/4885 |
| US-20240173416-A1 | PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USES THEREOF | GLP1R, GIPR, IAPP | NOD1 830/4885FOLH1 74/4885RIMKLA 2601/4885 |
| US-20260000770-A1 | LIQUID PHARMACEUTICAL COMPOSITIONS OF POLYPEPTIDE CONJUGATES AND METHODS OF USES THEREOF | GLP1R, GIPR, VIP | NOD1 832/4885FOLH1 1954/4885RIMKLA 3369/4885 |
| US-20220133856-A1 | POLYPEPTIDE CONJUGATES AND METHODS OF USES | GLP1R, GIPR, IAPP | NOD1 1241/4885FOLH1 64/4885RIMKLA 2555/4885 |
| US-11510990-B2 | Conjugates of fusion proteins of GLP-1 and FGF21 | GLP1R, GIPR, FGFR1 | NOD1 1107/4885FOLH1 141/4885RIMKLA 3513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.